Literature DB >> 11605352

Myocardial blood flow and flow reserve in response to short-term cyclical hormone replacement therapy in postmenopausal women.

C S Duvernoy1, J Rattenhuber, V Seifert-Klauss, F Bengel, C Meyer, M Schwaiger.   

Abstract

OBJECTIVES: To measure the effects of combined cyclical hormone replacement therapy (HRT) on myocardial blood flow (MBF) in postmenopausal women at high risk for coronary heart disease (CHD) and in women with documented CHD.
BACKGROUND: Estrogen restores endothelium-dependent vasodilation in response to acetylcholine in postmenopausal women, and it has a direct, endothelium-independent vasodilatory effect on coronary arteries.
METHODS: To determine whether coronary microcirculation can be affected by short-term, combined HRT, we performed positron emission tomography (PET) in two groups of women without previous HRT. Group I (n = 10) had one or more risk factors for CHD; group II (n = 8) had documented CHD and previous myocardial infarction. Group II was older (54 +/- 4 vs 59 +/- 5 y, P = .03) and had lower total cholesterol levels at baseline because of lipid-lowering therapy (244 +/- 31 vs 203 +/- 40 mg/dL, P = .03). Patients underwent baseline dynamic PET with N-13 ammonia at rest and during maximal adenosine-induced hyperemia to assess MBF. Each then began taking HRT (conjugated equine estrogen alone or with medroxyprogesterone acetate (MPA), administered in cyclical fashion), and returned for follow-up PET 46 +/- 12 days later.
RESULTS: There was no difference in resting MBF between groups I and II prior to starting therapy or at follow-up. Stress MBF and flow reserve (FR) tended to be higher in group I patients at baseline. MBF values remained unchanged at follow-up and resulted in similar FR values at baseline and during HRT for both groups. Women using only estrogen (n = 6) tended to show higher FR values after estrogen therapy, however.
CONCLUSIONS: Short-term HRT in postmenopausal women did not lead to improvements in MBF or FR. Combined cyclical HRT may not exert measurable effects on coronary microcirculation. MPA may attenuate estrogen effects on the coronaries, which may be largely endothelium-dependent.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11605352

Source DB:  PubMed          Journal:  J Gend Specif Med        ISSN: 1523-7036


  5 in total

1.  Assessment of coronary flow reserve and microcirculation: a clinical perspective.

Authors:  Roxana Campisi; Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2004 Jan-Feb       Impact factor: 5.952

2.  Myocardial blood flow: Putting it into clinical perspective.

Authors:  Thomas Hellmut Schindler
Journal:  J Nucl Cardiol       Date:  2015-12-28       Impact factor: 5.952

Review 3.  Role of PET in the evaluation and understanding of coronary physiology.

Authors:  Thomas H Schindler; Xiao-Li Zhang; Gabriella Vincenti; Leila Mhiri; René Lerch; Heinrich R Schelbert
Journal:  J Nucl Cardiol       Date:  2007-07       Impact factor: 5.952

4.  Effect of hormone replacement therapy on vasomotor function of the coronary microcirculation in post-menopausal women with medically treated cardiovascular risk factors.

Authors:  Thomas H Schindler; Roxana Campisi; Deborah Dorsey; John O Prior; Manfred Olschewski; James Sayre; Heinrich R Schelbert
Journal:  Eur Heart J       Date:  2009-02-26       Impact factor: 29.983

5.  Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC.

Authors:  Venkatesh L Murthy; Timothy M Bateman; Rob S Beanlands; Daniel S Berman; Salvador Borges-Neto; Panithaya Chareonthaitawee; Manuel D Cerqueira; Robert A deKemp; E Gordon DePuey; Vasken Dilsizian; Sharmila Dorbala; Edward P Ficaro; Ernest V Garcia; Henry Gewirtz; Gary V Heller; Howard C Lewin; Saurabh Malhotra; April Mann; Terrence D Ruddy; Thomas H Schindler; Ronald G Schwartz; Piotr J Slomka; Prem Soman; Marcelo F Di Carli; Andrew Einstein; Raymond Russell; James R Corbett
Journal:  J Nucl Cardiol       Date:  2018-02       Impact factor: 5.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.